Speakers - 2026

Title: Optimal Timing of ARV Initiation among patients with Toxoplasma Encephalitis: A Meta-analysis

Abstract

Toxoplasma encephalitis (TE) affects 10-40% of AIDS patients worldwide, with mortality rates of 10-50%. The optimal timing of antiretroviral therapy (ART) initiation remains controversial, balancing early immune recovery benefits against immune reconstitution inflammatory syndrome (IRIS) risks. A meta-analysis of six studies (2009-2025) encompassing 710 HIV patients with TE was conducted. Studies compared early (≤10 days) versus delayed (>21 days) ART initiation after anti-toxoplasma treatment. Primary outcomes included mortality and neurological sequelae. Random-effects models were used with heterogeneity assessed by I² statistics. Early ART initiation showed no significant overall mortality difference (pooled OR: 0.85, 95% CI: 0.42-1.72, p=0.65) but demonstrated significant mortality reduction at 24-week follow-up (pooled OR: 0.65, 95% CI: 0.50-0.83, p<0.001). Neurological sequelae increased non-significantly with early initiation (pooled OR: 1.28, 95% CI: 0.97-1.67, p=0.07). IRIS occurrence showed no significant difference between groups. Optimal outcomes occurred with ART initiation at 10-21 days post-diagnosis, balancing mortality reduction with minimized complications. The mortality benefit of early ART supports immune reconstitution advantages, while increased neurological sequelae raise safety concerns. The absence of significant IRIS differences suggests concurrent anti-toxoplasma therapy may reduce inflammatory responses. Study heterogeneity regarding timing definitions and geographic diversity affect interpretation. ART initiation between 10-21 days after anti-toxoplasma treatment provides optimal risk-benefit balance for most patients. Clinical decisions should incorporate individual factors including CD4 count, neurological severity, and healthcare resources. Standardized timing definitions and long-term outcome studies are needed.

What will the audience take away from presentation? 

• The most important takeaway of the study would be determination of the optimal timing at which antiretrovirals may be initiated wherein the risks and benefits may be more balanced.
• CNS Toxoplasmosis has a high mortality rate and this study would help in determining the proper course of management to increase the chances of survival of patients with concomitant infection of Toxoplasma Encephalitis and newly diagnosed HIV.
• The study may help in decreasing as well the likelihood for IRIS to occur especially in newly diagnosed patient since IRIS also has a very high mortality rate.
• This study will improve patient care in the areas in of minimal reach or areas without specialists and without adequate knowledge on management of CNSI and HIV.